CXCL9 and neoplasm: However, the aforementioned agonists of CXCL9/10 worked efficiently only when critical myeloid cells (M1-like macrophages and dendritic cells) presented within the tumor microenvironment (Hoch et al., 2022; Reschke and Gajewski, 2022).